An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study
- 200 Downloads
In patients receiving prophylactic lamivudine (LAM) and chemotherapy, hepatitis B virus (HBV) reactivation cannot be eliminated without knowing the latent causes and optimal management. In our previous study, virus breakthrough and relapse were highly suspected as potential virologic causes for HBV reactivation. Therefore, we reviewed 24 previous studies and 447 patients who underwent chemotherapy and prophylactic LAM, with an incidence of 7.2 % HBV reactivation. Virus breakthrough and relapse were seldom investigated in these studies. In addition, 72 patients that underwent prophylactic LAM and chemotherapy at our centers were also analyzed. Among them, eight patients developed virus breakthrough, with another nine developing virus relapse after discontinuation of LAM. Eight patients received antiviral modification, which included administration of adefovir for patients with virus breakthrough or resumption of LAM for patients with virus relapse and none of them developed HBV reactivation. In contrast, of the nine patients who did not receive antiviral modification, six developed HBV reactivation and two died. In conclusion, this study demonstrated that virus breakthrough and relapse were the critical causative factors of HBV reactivation in patients receiving chemotherapy and prophylactic LAM. An optimized antiviral modification strategy could effectively prevent HBV reactivation in patients with virus breakthrough or relapse.
KeywordsHBV reactivation Virus breakthrough Virus relapse Modified antiviral strategy Chemotherapy
This work was supported by the Science and Technology Planning Project of Guangdong Province, 2009B060700024 (to XY Wu), 2011B031800076 (to Q Lin), and 2011B031800014 (to M Dong).
Conflicts of interest
All authors have contributed equally and are in agreement with the content of the manuscript without any potential conflicts of interest.
- 4.Li X, Xing YF, Lin Q, Dong M, Wan XB, Wu XY. The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol. 2012;9(6):350; author reply doi: 10.1038/nrclinonc.2012.1-c1.
- 11.Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29(2):1237–41. doi: 10.1007/s12032-011-9974-0.PubMedCrossRefGoogle Scholar
- 15.Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29(3):889–96. doi: 10.1002/hep.510290321.PubMedCrossRefGoogle Scholar
- 22.Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci. 2003;18(6):849–54.PubMedGoogle Scholar
- 29.Long M, Jia W, Li S, Jin L, Wu J, Rao N, et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011;127(3):705–12. doi: 10.1007/s10549-011-1455-9.PubMedCrossRefGoogle Scholar
- 33.Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324–30.PubMedCrossRefGoogle Scholar